Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Single-Dose, Randomized, Three-Period Crossover Study to Evaluate the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Female Subjects of Non-Childbearing Potential

Next Previous
Trial Profile

A Phase 1, Open-Label, Single-Dose, Randomized, Three-Period Crossover Study to Evaluate the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Female Subjects of Non-Childbearing Potential

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Giredestrant (Primary) ; Giredestrant (Primary)
  • Indications Breast cancer; HER2 negative breast cancer
  • Focus Pharmacokinetics
  • Sponsors Genentech

Most Recent Events

  • 01 Feb 2023 Results assessing absorption, distribution, metabolism, and excretion of pexidartinib using radiolabeled drug from two clinical studies: NCT04037618 and NCT04274075 published in the Clinical Pharmacology in Drug Development
  • 15 Apr 2020 Status changed from active, no longer recruiting to completed.
  • 16 Mar 2020 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top